# Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

> **NCT00449046** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Bronchial Asthma

## Interventions

- **DRUG:** GW815SF Salmeterol/Fluticasone propionate(HFA MDI)

## Key facts

- **NCT ID:** NCT00449046
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449046, "Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00449046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*